Correvio Pharma’s (CORV) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Correvio Pharma (NASDAQ:CORV) in a report released on Thursday morning, AnalystRatings.com reports. They currently have a $7.00 target price on the stock.

Separately, ValuEngine raised shares of Correvio Pharma from a sell rating to a hold rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $7.00.

Shares of NASDAQ CORV opened at $1.76 on Thursday. The stock has a market cap of $84.85 million, a P/E ratio of -1.98 and a beta of 0.43. The firm has a 50 day moving average price of $1.89 and a 200 day moving average price of $2.66. The company has a debt-to-equity ratio of 7.21, a quick ratio of 2.42 and a current ratio of 2.80. Correvio Pharma has a 52-week low of $1.43 and a 52-week high of $5.24.

Correvio Pharma (NASDAQ:CORV) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.05). The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $7.64 million. Correvio Pharma had a negative net margin of 107.91% and a negative return on equity of 427.34%. Analysts predict that Correvio Pharma will post -0.71 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Correvio Pharma in the fourth quarter valued at approximately $39,000. Financial Counselors Inc. bought a new position in Correvio Pharma in the first quarter valued at approximately $116,000. LPL Financial LLC lifted its stake in Correvio Pharma by 177.1% in the second quarter. LPL Financial LLC now owns 63,855 shares of the company’s stock valued at $138,000 after buying an additional 40,815 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Correvio Pharma by 45.9% in the second quarter. Commonwealth Equity Services LLC now owns 105,623 shares of the company’s stock valued at $228,000 after buying an additional 33,250 shares in the last quarter. Finally, Columbia Pacific Advisors LLC lifted its stake in Correvio Pharma by 29.8% in the first quarter. Columbia Pacific Advisors LLC now owns 130,709 shares of the company’s stock valued at $413,000 after buying an additional 30,000 shares in the last quarter. 44.60% of the stock is currently owned by hedge funds and other institutional investors.

About Correvio Pharma

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Recommended Story: What does a neutral rating on stocks mean?

Analyst Recommendations for Correvio Pharma (NASDAQ:CORV)

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.